0000899243-22-001525.txt : 20220110
0000899243-22-001525.hdr.sgml : 20220110
20220110203556
ACCESSION NUMBER: 0000899243-22-001525
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220106
FILED AS OF DATE: 20220110
DATE AS OF CHANGE: 20220110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheng Isaac
CENTRAL INDEX KEY: 0001829696
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 22522542
MAIL ADDRESS:
STREET 1: C/O ATEA PHARMACEUTICALS, INC.
STREET 2: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-06
0
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001829696
Cheng Isaac
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2022-01-06
4
C
0
1409035
A
1409035
I
See Footnote
Common Stock
2022-01-06
4
C
0
6410964
A
7819999
I
See Footnote
Common Stock
2022-01-06
4
C
0
974107
A
8794106
I
See Footnote
Common Stock
2022-01-06
4
C
0
1621544
A
10415650
I
See Footnote
Common Stock
2022-01-06
4
P
0
6578
19.00
A
6578
D
Series A Preferred Stock
2022-01-06
4
C
0
1409035
0.00
D
Common Stock
1409035
0
I
See Footnote
Series B Preferred Stock
2022-01-06
4
C
0
6410964
0.00
D
Common Stock
6410964
0
I
See Footnote
Series C-1 Preferred Stock
2022-01-06
4
C
0
974107
0.00
D
Common Stock
974107
0
I
See Footnote
Series C-2 Preferred Stock
2022-01-06
4
C
0
1621544
0.00
D
Common Stock
1621544
0
I
See Footnote
Stock Option (Right to Buy)
19.00
2022-01-06
4
A
0
8400
0.00
A
2032-01-06
Common Stock
8400
8400
D
Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.
This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
/s/ Joshua B. Cohen, as Attorney-in-Fact
2022-01-10